Apyx Medical Shares Slump on Regulatory Woes

APYX stock is at risk of bearish analyst backlash

by Karee Venema

Published on Apr 2, 2019 at 10:00 AM

The shares of Apyx Medical Corp (NASDAQ:APYX) are down 36.6% at $4.40, slicing through a long-term level of support. The medical supplies maker said it has withdrawn a marketing application for Renuvion, a device used for skin resurfacing. The move comes after the U.S. Food and Drug Administration (FDA) questioned data irregularities.

After topping out at a nine-year high of $8.89 on Jan. 28, APYX pulled back sharply to test support at the $6 level and 200-day moving average -- a trendline that has ushered the shares higher for the last year, and caught a March sell-off. However, today's drop has the equity breaching both of these levels, and headed for its worst day since Dec. 5, 2002, when it lost 40%, and its lowest close since last June.

Analysts have yet to chime in, but there's plenty of room for downward revisions. While all three covering brokerage firms maintain a "buy" or better rating, the average 12-month price target of $10 is more than double APYX's current price.

And while short sellers are sidelined today with the stock on the short-sale restricted list, a recent batch of bearish bettors is likely cheering. Short interest on APYX stock is up 163% since late November, but the 196,159 shares currently sold short account for a slim 0.6% of Apyx Medical's available float.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
KEM Stocks Breaks Out Amid Buyout Buzz
Yageo group said it would buy Kemet in a $1.58 billion deal
FDA Delivers Another Blow to Solid Biosciences Stock
This is the second time a trial for the therapy has been placed on clinical hold in 2019
16-Hour "Jump Trades" Unlock New Profit Potential
Click to continue to advertiser's site.